Arterra Bioscience S.p.A.

Equities

ABS

IT0005386369

Biotechnology & Medical Research

Real-time Borsa Italiana Other stock markets 16:44:59 10/05/2024 BST			5-day change	1st Jan Change
1.97 ^EUR	0.00%		-1.50%	+18.67%

05-08	Mib bearish; focus on quarterlies	AN
05-07	Mib still in the green; Campari drags bullishness	AN

Arterra, decree consessione agevolzioni bando Rome Technopole

February 15, 2024 at 03:44 pm

(Alliance News) - Arterra Bioscience Spa let it be known Thursday that a decree has been signed granting facilities under the Rome Technopole program call approved by the University of Rome "Tor Vergata," for the research and development project called "Development of a digitized technology for the isolation of exosomes from plant cells and tissues-EXOPLANT."

The company is the lead partner in the project, which will be carried out in partnership with Innovation & Technology Provider Srl.

The project has a duration of 15 months and has an eligible investment for facilitation of EUR399,964.50.

The total facilitation requested and granted to support the project is EUR292,179.50, of which the share attributed to Arterra is EUR147,298.80, that attributed to ITP is EUR144,880.70.

Arterra Bioscience trades in the green by 2.3 percent at EUR1.78 per share.

By Claudia Cavaliere, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Go to the original article.
Legal disclaimer

Latest news about Arterra Bioscience S.p.A.

Mib bearish; focus on quarterlies	05-08	AN
Mib still in the green; Campari drags bullishness	05-07	AN
Indices in green; Iren hurt after Ad shutdown	05-07	AN
Stock markets up; results push UniCredit and Simone	05-07	AN
Mib in green; UniCredit and MPS boost profit	05-07	AN
Mib caresses 34,000; Amplifon bullish	05-06	AN
Arterra Bioscience increases turnover by 26 percent in first quarter	05-06	AN
ITALY GROWTH WINNERS & LOSERS: Askoll EVA rallying; Alfonsino trailing.	04-24	AN
Arterra Bioscience with profit down; board confirms dividend	04-02	AN
Futures down; China sets growth at 5 percent	03-05	AN
Mib slightly down; still strength on Saipem	03-04	AN
Mib opens higher, still good for banks	02-23	AN
Arterra, decree consessione agevolzioni bando Rome Technopole	02-15	AN
Arterra Bioscience closes 2023 with declining revenues	02-13	AN
Banks weigh on Mib in the red	02-13	AN
Futures down slightly; wait for U.S. CPI	02-13	AN
Mib bullish dragged by Saipem and Cucinelli	02-12	AN
Mib bullish; profit taking on MPS	02-08	AN
Arterra Bioscience closes nine months with revenues up	11-07	AN
Arterra Bioscience S.p.A.'s Equity Buyback announced on May 13, 2022, has expired.	27/10/23	CI
Arterra Bioscience buys back own shares for approximately EUR30,000	27/10/23	AN
Arterra Bioscience has purchased more than 11,200 of its own ordinary shares	20/10/23	AN
Arterra Bioscience has purchased more than 26,000 of its own ordinary shares	13/10/23	AN
Arterra Bioscience buys back own shares for more than EUR30,000	06/10/23	AN
Arterra Bioscience reduces profit in half-year; production value down	28/09/23	AN

Chart Arterra Bioscience S.p.A.

Duration

Period

More charts

Company Profile

Arterra Bioscience SpA is an Italy-based biotechnology company. It focuses on research and development of ingredients and natural solutions. By exploiting the potentialities of living organisms such as bacteria, yeasts, plants and animal cells, the Company develops products and processes that serve as enabling technologies and that find horizontal application in various industrial sectors, such as cosmetics, agriculture and nutraceutics. The Companyâs main activities and applications include development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds and the production of high-tech raw materials with application in different industrial fields. The Company collaborates with private companies, universities and research institutes all over the world.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARTERRA BIOSCIENCE S.P.A.	+18.67%	14.13M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research